Cancer Treatments
Total Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
489
NCT03315039
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 28, 2018
Completion: Jun 20, 2020
NCT03388749
Start: Dec 17, 2018
Completion: Feb 14, 2022
NCT04702503
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Phase: Phase 1
Start: Mar 8, 2019
Completion: Nov 15, 2020
NCT04887298
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
Start: Jun 5, 2021
Completion: Aug 6, 2024
NCT05195723
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
Start: May 11, 2022
Completion: Oct 24, 2022
NCT05319587
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Start: Sep 29, 2022
Completion: Aug 10, 2023
NCT05879250
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase: Phase 2
Role: Collaborator
Start: May 22, 2024
Completion: Dec 27, 2028
NCT06788756
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Phase: Phase 2/3
Start: Mar 12, 2025
Completion: Aug 31, 2030
Loading map...